Effects Of Interferon Therapy On Heart

Area of Science:

• Cardiology
• Hepatology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection affects 185 million globally, with 10 million in Pakistan.
• Interferon plus Ribavirin (IFN/RIB) is a primary HCV treatment with reported cardiovascular side effects.
• This study assessed the cardiac safety of interferon therapy in Pakistani patients.

Purpose of the Study:

• To evaluate the cardiac safety of interferon therapy in HCV patients.
• To identify potential cardiovascular adverse reactions associated with IFN/RIB treatment.

Main Methods:

• Echocardiography was performed on 102 HCV patients before, during, and after pegylated interferon and ribavirin therapy.
• Patients with pre-existing heart disease were excluded.
• The study spanned from November 2012 to August 2014.

Main Results:

• No acute cardiac events occurred in the 46 patients who completed treatment.
• All patients maintained normal biventricular systolic function post-therapy.
• Statistically significant findings included diastolic dysfunction and mild pericardial effusion in some patients.

Conclusions:

• Interferon therapy is cardiac safe for HCV patients with structurally normal hearts.
• Female patients showed a higher propensity for adverse events like diastolic dysfunction and pericardial effusion.
• Further research is needed on cardiac safety in patients with existing heart conditions.